Edition:
United Kingdom

Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

0.71USD
15 Dec 2017
Change (% chg)

$-0.07 (-8.99%)
Prev Close
$0.78
Open
$0.78
Day's High
$0.78
Day's Low
$0.70
Volume
109,295
Avg. Vol
156,488
52-wk High
$5.02
52-wk Low
$0.70

Select another date:

Wed, Nov 15 2017

BRIEF-Immune Pharmaceuticals reports Q3 results

* Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update

BRIEF-Immune Pharmac prices $18 mln public offering

* Immune Pharmaceuticals Inc announces pricing of $18,000,000 public offering of convertible preferred stock and warrants

BRIEF-Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab

* Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab in bullous pemphigoid

BRIEF-Immune Pharmaceuticals appoints Daniel Teper as CEO for Cytovia

* Immune Pharmaceuticals provides research and development and business update and summary of recent financial highlights.

BRIEF-Immune Pharmaceuticals files for non-timely 10-Q

* Immune Pharmaceuticals Inc files for non-timely 10-Q - sec filing Source text: (http://bit.ly/2fFbJWp) Further company coverage:

BRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia

* Immune Pharmaceuticals provides update on plan to implement a spin-off of Cytovia into a separate publicly traded oncology company

BRIEF-Immune Pharma announces filing of patent protecting use of ceplene

* Immune Pharmaceuticals announces filing of a patent protecting use of ceplene (histamine dihydrochloride) in hematologic cancers

BRIEF-Cytovia Inc enters agreement with Pint Pharma for licensing of Ceplene in Latin America

* Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America

BRIEF-Immune Pharmaceuticals' oncology unit announces additional clinical trial results on the efficacy of Ceplene in combination with low-dose IL-2 in patients with acute myeloid leukemia

* Immune Pharmaceuticals' oncology subsidiary, Cytovia, announces additional clinical trial results on the efficacy of Ceplene® in combination with low-dose IL-2 in patients with acute myeloid leukemia, recently published in leukemia, a leading Hematology Journal

BRIEF-Immune Pharmaceuticals files for offering of upto 1.4 mln shares

* Immune Pharmaceuticals Inc files for offering of upto 1.4 million shares of common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2t04Ovb) Further company coverage:

Select another date: